Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital

Clinical Microbiology and Infection

Volumn 12, Issue 1, 2006, Pages 75-80

  Bedini, Andrea ^a   Venturelli, C ^a   Mussini, C ^a   Guaraldi, G ^a   Codeluppi, M ^a   Borghi, V ^a   Rumpianesi, F ^a   Barchiesi, F ^b   Esposito, R ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Amphotericin B; Antifungal susceptibility; Bloodstream infections; Candida spp.; Posaconazole; Susceptibility

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; NYSTATIN; POSACONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD CULTURE; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CHILD; CONTROLLED STUDY; DRUG USE; EPIDEMIOLOGICAL DATA; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; INCIDENCE; INFANT; ITALY; KIDNEY TRANSPLANTATION; LABORATORY TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; TERTIARY HEALTH CARE;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; ISSATCHENKIA ORIENTALIS;

EID: 33644853104     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01310.x     Document Type: Article

References (34)

1. Beck-Sague CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167: 1247-1251.
2. Harbarth S, Reuf C, Francioli P et al. Nosocomial infections in Swiss university hospitals: A multi-centre survey and review of the published experience. Swiss-Noso Network. Schweiz Med Wochenschr 1999; 129: 1521-1528.
3. Edmond MB, Wallace SE, McClish DK et al. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999; 29: 239-244.
4. Coello R, Charlett A, Ward V et al. Device-related sources of bacteraemia in English hospitals-Opportunities for the prevention of hospital acquired bacteraemia. J Hosp Infect 2003; 53: 46-57.
5. Kam LW, Lin JD. Management of systemic candidal infections in the intensive care unit. Am J Health Syst Pharm 2002; 59: 33-41.
6. Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-1079.
7. Weinstein MP, Towns ML, Quartey SM et al. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24: 584-602.
8. Wey SB, Mori M, Pfaller MA et al. Hospital-acquired candidemia: The attributable mortality and excess length of stay. Arch Intern Med 1998; 148: 2642-2645.
9. Wenzel RP, Edmond MB. The impact of hospital-acquired bloodstream infections. Emerg Infect Dis 2001; 7: 174-177.
10. Abi-Said D, Anaissie E, Uzun O et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-1128.
11. Chen YC, Chang SC, Sun CC et al. Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993. Infect Control Hosp Epidemiol 1997; 18: 369-375.
12. Nguyen MH, Peacock JE, Morris AJ et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617-623.
13. Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-2061.
14. Chandrasekar PH, Gatny CM. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplant Team. J Antimicrob Chemother 1994; 33: 309-318.
15. Wingard JR, Merz WG, Rinaldi MG et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-1277.
16. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect 2001; 7 (suppl 2): 1-7.
17. Barchiesi F, Arzeni D, Fothergill AW et al. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 2000; 44: 226-229.
18. Pfaller MA, Messer SA, Hollis RJ et al. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001; 45: 2862-2864.
19. Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1504-1507.
20. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. Wayne, PA: NCCLS, 1997.
21. Rex JH, Pfaller MA, Galgiani NJ et al. Development of interpretative breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections. Clin Infect Dis 1997; 24: 235-247.
22. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
23. Luzzati R, Amalfitano G, Lazzarini L et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur J Clin Microbiol Infect Dis 2000; 19: 602-607.
24. Tortorano AM, Peman J, Bernhardt H et al. Epidemiology of candidemia in Europe: Results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-322.
25. Gottfredsson M, Vredenburgh JJ, Xu J et al. Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation. Cancer 2003; 98: 24-30.
26. Krcmery V, Barnes AJ. Non- albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-260.
27. Rex JH, Pfaller MA, Walsh TJ et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643-658.
28. Pfaller MA, Messer SA, Boyken L et al. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: Global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46: 3518-3521.
29. Tortorano AM, Rigoni AL, Biraghi E et al. The European Confederation of Medical Mycology (ECMM) survey of candidemia in Italy: Antifungal susceptibility patterns of 261 non- albicans Candida isolates from blood. J Antimicrob Chemother 2003; 52: 679-682.
30. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002; 40: 3551-3557.
31. Pfaller MA, Diekema DJ, Jones RN et al. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254-3259.
32. Levy I, Rubin LG, Vasishtha S et al. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 1998; 26: 1086-1088.
33. Weems JJ, Chamberland ME, Ward J et al. Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers. J Clin Microbiol 1987; 25: 1029-1032.
34. Levin AS, Costa SF, Mussi NS et al. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis 1998; 30: 243-249.